Author's response to reviews
|
|
- Louisa Bailey
- 6 years ago
- Views:
Transcription
1 Author's response to reviews Title: The Older People, Omega-3, and Cognitive Health (EPOCH) trial design and methodology: A randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. Authors: Vanessa Danthiir (vanessa.danthiir@csiro.au) Nicholas R Burns (nicholas.burns@adelaide.edu.au) Ted Nettelbeck (ted.nettelbeck@adelaide.edu.au) Carlene Wilson (carlene.wilson@flinders.edu.au) Gary Wittert (gary.wittert@adelaide.edu.au) Version: 2 Date: 14 September 2011 Author's response to reviews: see over
2 14 th September, 2011 Dear Editors, Please find below our response to the reviewer s comments on our manuscript, The Older People, Omega-3, and Cognitive Health (EPOCH) trial design and methodology: A randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. We appreciate and thank the reviewers for their constructive comments. We have addressed each of these as detailed below. As requested, we have also now included a list of abbreviations used in the manuscript, along with their meanings, on pp Sincerely, Vanessa Danthiir Responses to reviewers Reviewer: Natalie Sinn 1. It would be helpful to clarify up front that n-3 blood analysis was a measure of erythrocyte (red blood cell) PUFA status which is very important. We have now clearly stated that n-3 PUFAs were measured in erythrocyte membranes (p12). 2. Page 10: Participants had to be willing to not commence their own n-3 supplementation throughout the study and were excluded if they were taking n-3 supplements but no mention is made of fish consumption i.e. were they asked to limit their normal consumption of fatty fish to, for example, less than once a week or fortnight? As the authors note, the daily supplement dosage is equivalent to the n-3 PUFAs in 150g of salmon which has a similar impact on cell membrane composition. We did not ask participants to limit their consumption of fatty fish. We did ask participants to maintain their usual diet over the course of the study, and have now included a statement to this effect [page 11]. We collected detailed data relating to dietary n-3 PUFA intake at each of the four time points, allowing us to control for any effect of changes, or differences in dietary n-3 PUFA intake on outcomes [this has now been noted on page 15].
3 3. Page 10: The cut-off score of 24/30 on the MMSE for possible dementia is more commonly used as a cut-off for mild cognitive impairment, whereas 18/30 tends to be a cut-off for possible dementia. Therefore perhaps the methodology needs to be modified to state that people with dementia were excluded (i.e. that elderly people ranging from mild cognitive impairment to normal cognitive function were included in the study). The traditional MMSE cut-off score for identifying cognitive impairment and possible dementia (Lezak, 1984) was used, consistent with our exclusion criteria which specify as exclusions dementia [and] received a score less than less than 22/27 on a telephone-administered version [37] of the Minimental State Examination (MMSE) (equivalent to < 24/30 on the standard MMSE, the traditional cut-off for possible dementia). Although we have used a cut-off score that is used to screen out demented older adults, we agree that the suggested cut-off scores vary between publications and populations, with some publications suggesting that for highly educated adults, ie. University educated, the cut-off should be higher. However, less than 24 is often stated as the traditional cut-off for dementia using the MMSE, and for this reason that was the cut-off score utilised. We have clarified (p. 7): The primary aim of the current trial was to comprehensively assess over 18-months the efficacy of a DHA-rich fish-oil supplement on slowing cognitive decline in non-demented older adults. 4. Page 10: In the exclusion criteria the MMSE cut-off is stated as <24/30 whereas under Screening and information sessions it is given as <22/27 both cited as the telephone administered versions. This inconsistency needs to be clarified. Also, what was the purpose of administering the complete MMSE following written consent was it for further screening or an outcome measure? I think this needs to be clarified here We have now clarified the cut-off point on MMSE used to exclude participants; in both instances we say that participants scoring less that 22/27 on the telephone administered MMSE were excluded, and note that this score is equivalent to the traditional cut-off of less than 24/30 on the standard MMSE. p10: less than 22/27 on a telephone-administered version [37] of the Mini-mental State Examination (MMSE) (equivalent to < 24/30 on the standard MMSE, the traditional cut-off for possible dementia). We have clarified the purpose of administering the complete MMSE, on page 11: administration of the complete MMSE was undertaken, to corroborate the telephone screening and to serve as an outcome measure. 5. Page 12: would be useful to clarify that each placebo capsule contained 990mg of olive oil (if that is the case).
4 oil. We have clarified (p.13) that each placebo contained 990mg of olive 6. When asking participants which experimental group they thought they were in, to assess blinding adequacy, were they asked why they thought they were in a specific group? I.e. it should be considered that some beneficial effects of fish oil include reduced joint pain which might lead people to suspect that they are in the treatment group even if blinding is effective. Participants were not asked why they thought they were in a specific group, although in hindsight this would have been interesting information to collect. 7. Does the statistical analysis take multiple assessments into consideration? I note here that factor analysis was conducted to potentially reduce the number of assessments; will that also be used to reduce the number of variables in the final analysis? If so, this should be clarified. Modelling of latent cognitive variables will be employed in the final analyses to reduce the number of tests that will be conducted, following the confirmatory factor analyses of the baseline data, and providing the cognitive factors prove to be measuring the same construct across time. The assessment of intervention effects will be conducted on these cognitive factors (as opposed to individual tests). We have clarified this now on pp22-23: The cognitive domains will be modelled as latent variables, providing the cognitive factors prove to be measuring the same construct across time, following the initial planned modelling of the tasks and cognitive factors on baseline data using confirmatory factor analysis (CFA). The main effect of the intervention on each cognitive domain will initially be assessed separately Is it appropriate to give actual recruitment numbers and missing data in the methodology paper or would they be more appropriately stated in the paper reporting study outcomes? On consideration, we agree with the reviewer that details on actual recruitment numbers and missing data would be most appropriately stated in the paper reporting study outcomes, hence we have deleted mention of these. However, the one exception is the numbers for baseline since confirmatory factor analysis was conducted on this data and reported in the current MS; the N for the baseline analyses is included on p24. The following sentences have been deleted: p8. Recruitment commenced in June 2007 and data collection finished Nov 2009; 391 participants completed baseline assessment and 354 completed the final assessment. p.26 The trial has been completed with excellent retention rates and minimal missing data.
5 Reviewer Alan Dangour 1. Was a systematic review conducted to inform the section on crosssectional and prospective studies? If not, then statements such as "To date, only one published study has reported a negative relationship between cognition and biomarkers of n-3 LC PUFAs [22] or dietary intake levels" are not appropriate. How can you be sure? Please modify these background sections (which appear not to be based on systematic reviews) accordingly. A comprehensive but not systematic review was conducted to inform the background sections on cross-sectional and prospective studies, and we have therefore modified the section on cross-sectional and prospective studies accordingly, as suggested by the reviewer. The modifications are in bold in the instances cited below: p4. only a handful of the aforementioned studies that also examined relationships between cognitive outcomes and dietary intake levels of n-3 LC PUFAs have found significant positive relationships p5. The sentence cited by the reviewer has been changed to ; in contrast, Laurin et al [22] reported a negative relationship between cognition and biomarkers of n-3 LC PUFAs. 2. In the section on participant recruitment you state in one place that you exclude individuals with an MMSE score of <24 out of 30, while a few lines later you say you exclude those with an MMSE score of <22 out of 27. I understand that this is because in the latter case this is a telephone version of the test, but this is not particularly clear in the paper. This has now been clarified; please see our response to the same point by the other reviewer, at point 2 above. 3. You must provide more information on the composition of the "fish oil" added to the placebo capsule, provide a rationale for its addition and justify the inclusion of the "intervention" in the placebo arm. On p.13 we have now provided detail of the composition of the fish oil added to the placebo capsule [ equivalent to 1.8mg EPA and 1.2mg DHA ] On pages 11 and 13 we have added more detail [in bold below] to justify the addition of the small amount of fish-oil to the placebo capsules: p11. and 1% fish-oil was added to the placebo oil to help maintain blinding in the event of, for example, accidental piercing of the capsules or an aftertaste. p13. The minimal amount of fish oil was added to help mask any difference between the placebo and active capsules and was not processed under nitrogen, rendering it less potent than that used in the active formulation.
6 4. You have collected a huge amount of data at multiple time points and it's really important to be clear about what you plan to do with it. For example, you have collected a measures of "carotenoids, folate and B12" at baseline and final appointment. What are you going to do with these? Is there reason to believe that they will change because of the intervention? Are you planning to include them as co-variates? Are you just interested in cross-sectional associations of levels and outcome variables? At present you include the statment "Analyses may include these markers as covariates or mediating variables." This is not sufficient. More clarity is needed for all the variables you have collected. We have now included the following statement on page 7: The trial was set within the broader context of examining nutritional, health, and lifestyle factors associated with better cognitive and well-being outcomes in the elderly, both cross-sectionally and longitudinally. Detail relating to the variables collected, in particular the purpose of including each, has been included see pp On page 14 we have included the following: At baseline and final assessment, blood was taken for measurement of: carotenoids, folate, and Vitamin B12, all having been associated with cognitive functioning in the elderly, to examine cross-sectional associations between these measures and outcomes, and if necessary in the intervention analyses, to control for any potential differences between groups at baseline or any changes in these measures that differ between groups (despite randomisation) 5. I would like to see a list of specific secondary outcome measures rather than broad categories such as "lipid metabolism" or "mood". Please specify each secondary outcome measure that will be report. I would also urge you to think carefully about your secondary outcomes - how many of these do you really believe might be influenced by the intervention? Do they all need to be listed as secondary outcomes? Also, surely change in n-3 LCP status is a measure of compliance rather than a secondary outcome measure? We have revised our secondary outcomes on p16. so that specifics, as opposed to broad categories, are given, as follows. We have removed broadly defined wellbeing and functional capacity, encompassing, and replaced mood with positive and negative affect, and added life satisfaction. We have replaced markers of lipid metabolism, inflammation, and oxidative stress with triglycerides, total cholesterol, HDL, LDL, homocysteine, CRP, MDA. For each measure that is listed there is reason to believe that the intervention might affect it. We have removed n-3 LCP status from the list of secondary outcomes, although we will also be investigating whether changes in n-3 LCP status are related to changes in the cognitive outcomes.
7 6. The number of tests conducted on each participant is large. It is important to state how long the appointments took and the order in which the tests were administered. Also, some statement on participant burden/fatigue and how you over-came it would be useful. We have now expanded upon the previous details of the duration of the testing session, on p17, to now read: The testing session lasted approximately four hours and consisted of four sections of around 50 min duration, with a break of approximately 10 min between each section. During this break participants were provided with standard refreshments, including decaffeinated tea/coffee. The speed tasks were interspersed between the accuracy based tasks and to also help minimise fatigue, paper and pencil tasks were interspersed with computerised tasks, which were administered in an adjacent room. The order of tasks was fixed across participants and testing sessions. We have now noted in the appendix the order of presentation of the tasks. The sequence number is listed after the name of each task. 7. I think it would be useful to provide more information on the rate of decline in cognitive function expected in the placebo group. As you are aware, we in the OPAL study found no change in cognitive function over 24 months of intervention. There are of course differences between trials, (you are conducting a trial in a population group with a wider age category (65-90), and are measuring cognitive function 4 times and conducting growth curve modelling), but your trial is shorter - and trial duration is likely to be critical. So some statement to support your assumption that there will be a measurable decline in cognitive function in the placebo group over 18 months seems appropriate. Normative data on rates of decline with ageing for cognitive tasks does not currently exist; hence we cannot state an expected rate of cognitive decline for the placebo group. However, we have amended (in bold) our statement on p8 regarding cognitive decline to give an indication of potential magnitude and support our statement that decline of the cognitive abilities vulnerable to ageing effects begins by the early 30s so although participants were screened for cognitive impairment, all were expected to experience cognitive decline to some extent. For instance, meta-analyses of cross-sectional data suggest that processing speed declines, on average, by approximately 20% at age 40 and by 40-60% at age 80. Further, under the section on the cognitive test battery, on p16, we have already noted that the focus of the battery was on constructs that are sensitive to age-related changes, and that Most of the cognitive domains were assessed using tasks in which speed of response was the main outcome measure. The psychometric properties of speed tasks make them more sensitive to subtle cognitive changes.
8 8. I propose that the statistical analysis section is checked by an expert. Two of the authors (VD and NB) are experienced in latent variable modelling and together have numerous publications utilising these types of analyses. Further, the statistical analysis section on the intervention analyses and power was incorporated in the successful proposal for funding for the trial to the Australian National Health and Medical Research Council, which was reviewed by a grant review panel (consisting of on average, ten members), and two expert external assessors. We believe one of these expert reviewers was knowledgeable and experienced in latent growth curve modelling. Further, the main reference for the analytical framework to be applied for the latent growth curve modelling of the intervention and for the power calculation has been provided as a citation on pp (Muthén & Curran, 1997). Lezak, M. D. (1984). Neuropsychological assessment in behavioral toxicology--developing techniques and interpretative issues. Scand J Work Environ Health, 10 Suppl 1, Muthén, B. O., & Curran, P. J. (1997). General longitudinal modeling of individual differences in experimental designs: A latent variable framework for analysis and power estimation. Psychological Methods, 2, Newkirk, L. A., Kim, J. M., Thompson, J. M., Tinklenberg, J. R., Yesavage, J. A., & Taylor, J. L. (2004). Validation of a 26-point telephone version of the Mini-Mental State Examination. J Geriatr Psychiatry Neurol, 17(2),
Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD
Prevention of dementia Author Daniel Press, MD Michael Alexander, MD Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD Deputy Editor Janet L Wilterdink, MD Last literature review version
More informationThe Better Health News2
February, 2009 Volume 4, Issue 1 The Better Health News2 Special Interest Articles: Curry and Disease Name That Food Nutrition and Disease Diet, Supplmentation and Dementia Elemental Diet and Crohn s Disease
More informationUnderstanding the potential of cognitive ingredients. Dr Carrie Ruxton Freelance Dietitian
Understanding the potential of cognitive ingredients Dr Carrie Ruxton Freelance Dietitian Cognitive health important across the lifecycle Higher IQ Diet & Supplements Brain development Slower cognitive
More informationTiago Villanueva MD Associate Editor, The BMJ. 9 January Dear Dr. Villanueva,
Tiago Villanueva MD Associate Editor, The BMJ 9 January 2018 Dear Dr. Villanueva, Thank you for your thoughtful re-review of our Manuscript (BMJ.2017.041528) entitled "Immune-related Toxicities in PD-1
More informationFuture directions for nutritional and therapeutic research in omega-3 3 lipids
Future directions for nutritional and therapeutic research in omega-3 3 lipids Philip Calder Professor of Nutritional Immunology University of Southampton Aim To review dietary sources and intakes of long
More informationAuthor's response to reviews
Author's response to reviews Title:Placebo-Controlled Randomized Clinical Trial of Fish Oil's Impact on Fatigue, Quality of Life, and Disease Activity in Systemic Lupus Erythematosus Authors: Cristina
More informationThe role of omega-3 fatty acids as a treatment for bipolar disorder
The role of omega-3 fatty acids as a treatment for bipolar disorder Research into omega-3 fatty acids as a possible treatment for mood disorders is a new and interesting area of research Although research
More informationT H E B E T T E R H E A L T H N E W S
Dr. Paul G. Varnas & WholeHealthAmerica.com present V O L U M E 7, I S S U E 2 T H E B E T T E R H E A L T H N E W S F E B R U A R Y, 2 0 1 0 D E M E N T I A A N D E X E R C I S E L E T S H E A R I T F
More informationHealth effects of consuming 2 portions per week of Scottish farmed salmon raised on different feeding regimes. Baukje de Roos
Health effects of consuming 2 portions per week of Scottish farmed salmon raised on different feeding regimes Baukje de Roos Sustainable sources of fish as food PROGRAMME Aquaculture has the potential
More informationLIFETIME DIET AND COGNITION IN OLDER PEOPLE
LIFETIME DIET AND COGNITION IN OLDER PEOPLE Diane E. Hosking BA, BHSc (Hons) School of Psychology Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy September 2013 ii Abstract
More informationAuthor's response to reviews
Author's response to reviews Title: A multicentre, double-blind, randomised, controlled, parallel-group study of the effectiveness of a pharmacist-acquired medication history in an emergency department
More informationregulates the opening of blood vessels, important for unhindered blood flow.
Vitamin E AT A GLANCE Introduction The term vitamin E describes a family of eight related, fat-soluble molecules. Among these, alphatocopherol has the highest biological activity and is the most abundant
More informationRisk Factors Associated with Cognitive Aging. Andrea Z. LaCroix, PhD. for the IOM Committee on the Public Health Dimensions of Cognitive Aging
Risk Factors Associated with Cognitive Aging Andrea Z. LaCroix, PhD. for the IOM Committee on the Public Health Dimensions of Cognitive Aging Lifestyle and Physical Environment Risk & Protective Factors
More informationTitle:Systematic review and meta-analysis of the effect of increased vegetable and fruit consumption on body weight and energy intake
Author's response to reviews Title:Systematic review and meta-analysis of the effect of increased vegetable and fruit consumption on body weight and energy intake Authors: Oliver T Mytton (otm21@medschl.cam.ac.uk)
More informationWeight Loss NOTES. [Diploma in Weight Loss]
Weight Loss NOTES [Diploma in Weight Loss] Fat s: The good, the bad and the ugly Fat s function in your body 1. Energy stores 2. Muscle fuel 3. Transportation 4. Cell membrane 5. Padding 6. Muscle fuel
More informationAuthor's response to reviews
Author's response to reviews Title: Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial
More informationThere is more scientific evidence behind the cardiovascular benefits of fish oil than nearly any other nutritional supplement
n Provides optimal support for heart health n Reduces triglyceride levels n Reduces cardiovascular risk factors 7, 8 n Complements statin drug therapy n Optimizes circulation and blood vessel function
More informationDietary omega-3 fatty acids and risk of type-2 diabetes: Lack of antioxidants?
Dietary omega-3 fatty acids and risk of type-2 diabetes: Lack of antioxidants? American Journal of Clinical Nutrition August 2011; Vol. 94; No. 2; pp. 618-619 Bjarne Osterud This author cites evidence
More informationTHE IMPORTANCE OF KNOWING YOUR OMEGA-3 INDEX: RECENT FINDINGS AND IMPLICATIONS FOR PUBLIC HEALTH PEOPLE MATTER PLANET MATTERS PROFIT MATTERS
THE IMPORTANCE OF KNOWING YOUR OMEGA-3 INDEX: RECENT FINDINGS AND IMPLICATIONS FOR PUBLIC HEALTH PEOPLE MATTER PLANET MATTERS PROFIT MATTERS Andreas Berg Storsve PhD, Director R&D 9.7 Billion people 2x
More informationTHE TRUTH ABOUT THE VITAL STUDY ON OMEGA-3 and VITAMIN D
THE TRUTH ABOUT THE VITAL STUDY ON OMEGA-3 and VITAMIN D There have been two recent publications regarding the findings from the VITAL study that have gotten a lot of media attention because of their conclusions
More informationSCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy
SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to n-3 polyunsaturated fatty acids (n-3 PUFAs) and nutrient tasks and interactions (ID 574), increase in calcium absorption
More informationJuly 13, Dear Ms. Davis:
July 13, 2010 Carole Davis Co-Executive Secretary and Designated Federal Officer of the Dietary Guidelines Advisory Committee Center for Nutrition Policy and Promotion U.S. Department of Agriculture 3101
More informationAuthor s response to reviews
Author s response to reviews Title: The validity of a professional competence tool for physiotherapy students in simulationbased clinical education: a Rasch analysis Authors: Belinda Judd (belinda.judd@sydney.edu.au)
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
23 June 2016 EMA/CHMP/345847/2015 Committee for Medicinal products for Human Use Overview of comments received on ''Guideline on clinical investigation of medicinal products in the treatment of hypertension'
More informationDietary Reference Values: a Tool for Public Health
HOGE GEZONDHEISRAAD Dietary Reference Values: a Tool for Public Health CONSEIL SUPERIEUR DE LA SANTE Belgian Dietary Reference Values for Energy and Macronutrients: FATS G. De Backer Brussels, February
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Ball State University
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationDear Dr. Villanueva,
22-12-2017 Dear Dr. Villanueva, We would like to thank you for your interest in our paper and the opportunity to resubmit our manuscript Living network meta-analysis for reducing research waste: an empirical
More informationEUROPEAN COMMISSION SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 13 JUNE 2014
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Brussels, SANCO G ARES(2014)2253750 SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 13 JUNE
More informationNutritional intervention in early Alzheimer s disease. Sasha Newsam, PhD Global Medical Affairs Manager Nutricia
Nutritional intervention in early Alzheimer s disease Sasha Newsam, PhD Global Medical Affairs Manager Nutricia Agenda Nutrition and brain function Single nutrient intervention Diet and risk of Alzheimer
More informationCanada would provide a proposed draft definition for consideration by the next session based on these comments.
E Agenda Item 7 CX/FL 11/39/14-Rev1 JOINT FAO/WHO FOOD STANDARDS PROGRAM CODEX COMMITTEE ON FOOD LABELLING Thirty-ninth Session Québec City, Canada 9 13 May 2011 Proposed Draft Definition of Nutrient Reference
More informationthé formula for a perfect balance PLUS
thé formula for a perfect balance PLUS Thé formula for a perfect balance PLUS 2 Why? Minami offers omega-3 nutritional supplements in a very high concentration, with scientifically proven effects and benefits.
More informationNEWS & VIEWS. Hole in the diet-heart hypothesis?
NEWS & VIEWS Hole in the diet-heart hypothesis? Philip C. Calder Faculty of Medicine, University of Southampton, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom and
More informationILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet
ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet 03-04 July 2014, Milan, Italy Nutritional effects on cognitive ageing Trial data Dr. Ir. Ondine van
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationPlease find attached the detailed reply to all reviewer s comments/suggestions.
Author s response to reviews Title: The Impact of the Time of Drug Administration on the Effectiveness of Combined Treatment of Hypercholesterolemia with ROSuvastatin and EZEtimibe (RosEze): study protocol
More informationNutrients for healthy ageing of mind and body. Carrie Ruxton PhD RD On behalf of the Health Supplements Information Service
Nutrients for healthy ageing of mind and body Carrie Ruxton PhD RD On behalf of the Health Supplements Information Service Life expectancy is increasing Office of National Statistics, 2014 But: we spend
More informationthé formula for a perfect balance
thé formula for a perfect balance Why? Minami offers omega-3 nutritional supplements in a very high concentration, with scientifically proven effects and benefits. Thé formula for a perfect balance The
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationPattern of lipid biomarkers and risk of cardiovascular disease
Pattern of lipid biomarkers and risk of cardiovascular disease Robert Clarke Clinical Trial Service Unit University of Oxford 9 January 2017 Biomarkers for dietary fats Blood lipids (LDL, HDL, triglycerides,
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationNational Institute for Health and Clinical Excellence. Health Technology Appraisal. Prucalopride for the treatment of chronic constipation in women
Health Technology Appraisal Summary form Prucalopride for the treatment of chronic constipation in women Comment 1: the draft remit Appropriateness Movetis Movetis entirely welcomes the opportunity to
More informationWhy. Children Need Healthy Fat?
Why Children Need Healthy Fat? Fat has always been associated with being harmful to our health. Too much fat intake is said to cause many diseases such as obesity, heart attack, diabetes and the list goes
More informationAuthor's response to reviews
Author's response to reviews Title: Associations between toenail arsenic accumulation and dietary factors in a New Hampshire populationassociations between toenail arsenic accumulation and dietary factors
More informationName of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active
More informationAuthor's response to reviews
Author's response to reviews Title: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled
More informationReflection paper on assessment of cardiovascular safety profile of medicinal products
25 February 2016 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on assessment of cardiovascular safety profile of medicinal products Draft agreed by Cardiovascular
More informationAuthor's response to reviews
Author's response to reviews Title: Effects of a commercial product containing Guarana on psychological well-being, anxiety and mood: a single-blind, placebo-controlled study in heathy subjects Authors:
More informationEvidence-Based Review Process to Link Dietary Factors with Chronic Disease Case Study: Cardiovascular Disease and n- 3 Fatty Acids
Evidence-Based Review Process to Link Dietary Factors with Chronic Disease Case Study: Cardiovascular Disease and n- 3 Fatty Acids Alice H. Lichtenstein, D.Sc. Gershoff Professor of Nutrition Science and
More informationPerception and insights on fats and fatty acids: knowledge of fat quality of the diet
Perception and insights on fats and fatty acids: knowledge of fat quality of the diet Background Research indicates that consumers nowadays are very aware of their health and the major role nutrition plays
More informationDietary Supplements, Caffeine, and Cognitive Aging
Institute of Medicine Committee on the Public Health Dimensions of the National Academies Beckman Center of the National Academies Irvine, CA June 9, 2014 Dietary Supplements, Caffeine, and Cognitive Aging
More informationTitle: Prevalence of sexual, physical and emotional abuse in the Norwegian Mother and Child Cohort Study
Author's response to reviews Title: Prevalence of sexual, physical and emotional abuse in the Norwegian Mother and Child Cohort Study Authors: Marie F Sorbo (marie.flem.sorbo@ntnu.no) Hilde Grimstad (hilde.grimstad@ntnu.no)
More informationNutrition & the healthy ageing of the brain
School of something FACULTY OF OTHER Nutrition & the healthy ageing of the brain Professor Louise Dye Chair in Nutrition and Behaviour Human Appetite Research Unit Institute of Psychological Sciences University
More informationGENERAL PRINCIPLES ON FLEXIBILITY OF WORDING FOR HEALTH CLAIMS
GENERAL PRINCIPLES ON FLEXIBILITY OF WORDING FOR HEALTH CLAIMS These general principles were presented for the first time at an informal meeting in Brussels on 19 June 2012. Experts from 17 Member States
More informationInstrument for the assessment of systematic reviews and meta-analysis
Appendix II Annex II Instruments for the assessment of evidence As detailed in the main body of the methodological appendix (Appendix II, "Description of the methodology utilised for the collection, assessment
More informationAlternative Methods for Assessing the Fit of Structural Equation Models in Developmental Research
Alternative Methods for Assessing the Fit of Structural Equation Models in Developmental Research Michael T. Willoughby, B.S. & Patrick J. Curran, Ph.D. Duke University Abstract Structural Equation Modeling
More information15/10/2018. A Functional Approach to Neurodegeneration. Functional Medicine for Alzheimer s Patients. Belinda Reynolds B.Sc.Nut.Diet.
A Functional Approach to Neurodegeneration Belinda Reynolds B.Sc.Nut.Diet. (Hons) 1 Functional Medicine for Alzheimer s Patients Source: http://www.dailymail.co.uk/health/article-3644980/scientists-reverse-memory-loss-time-alzheimer-spatients-changes-sleep-diet-medication-exercise.html
More informationTHE PROBLEM OMEGA 3. pure
p2 THE PROBLEM Essential fatty acids (EFAs) are polyunsaturated fats that our bodies need but cannot produce. Therefore, they must be consumed through food or supplements. Omega 3 and Omega 6 are EFAs.
More informationSCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy
SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to echium oil and maintenance of normal blood concentrations of triglycerides (ID 548) pursuant to Article 13(1) of
More informationCetoleic acid makes pelagic fish more healthy
Cetoleic acid makes pelagic fish more healthy WORKSHOP IN FISHMEAL AND FISH OIL, NOVEMBER 2018 Bente Ruyter Nofima Omega-3 fatty acids and health Eye Brain Cell membrane The marine omega-3 fatty acids
More informationFeatured Topic: Glutathione (5 slides)
Featured Topic: Glutathione (5 slides) Glutathione The body can make two antioxidants the rest must be obtained in the diet One is superoxide dismutase and the other is glutathione Mechanism of action
More informationThe ERA JUMP Study: Reevaluating the Omega- 3 Index
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/the-era-jump-study-reevaluating-the-omega-3-
More informationRe: Food-frequency questionnaire for assessing long-chain ω-3 fatty-acid intake
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2013 Re: Food-frequency questionnaire for assessing long-chain ω-3 fatty-acid
More informationAlzheimer s Disease (AD) and Dietary Supplementation George C. SPATHARAKIS
Alzheimer s Disease (AD) and Dietary Supplementation George C. SPATHARAKIS Geriatrician Gerontologist, Thessaloniki, george_spatharakis@yahoo.com INTRODUCTION Although it is well established that AD constitutes
More informationAAOCS 10 th Biennial Conference Barossa Valley, September Presenter: Petter-Arnt Hals MSc PhD Co-authors: Nils Hoem, Xiaoli Wang, Yong-Fu Xiao
Effects of a purified, omega-3 rich krill oil phospholipid on cardiovascular disease risk factors and fatty acid composition of erythrocyte membranes in non-human primates AAOCS 10 th Biennial Conference
More informationOmega-3 supplementation promotes key anti-inflammatory pathways that naturally support back, neck, and joint health and mobility
n Promotes key anti-inflammatory pathways n Promotes joint mobility and flexibility n Is a natural adjunct to conventional therapies n Is safe for long-term use Omega-3 supplementation promotes key anti-inflammatory
More informationTHE OMEGA 3 MANIFESTO
THE OMEGA 3 MANIFESTO Copyright 2015 by PacificCoast NutriLabs All rights reserved. No part of this book may be reproduced by any means whatsoever without the written permission from PacificCoast NutriLabs,
More informationHealth benefits of Omega-7 and the potential for Macadamia s.
Health benefits of Omega-7 and the potential for Macadamia s. Bianca Swanepoel & Lize Meades North-West University (Potchefstroom campus) Your logo or logos if you have more than one (edit in Slide Master)
More information17 MAY SEOUL. IADSA Annual General Meeting Codex Alimentarius / Omega 3
17 MAY SEOUL IADSA Annual General Meeting Codex Alimentarius / Omega 3 Codex Alimentarius CCNSFDU NRV/NCD EPA DHA NRV NCD BASIS FOR NRVs-NCD Need for: What are NRVs-NCD? NRVs-NCD stands for Nutrient Reference
More informationHypomagnesemia May Lead to Insulin Resistance
Hypomagnesemia May Lead to Insulin Resistance Nutritional Biochemistry NDFS 435 21 February 2013 Heidi Washburn Dr. Parker Hypomagnesaemia has been associated with increased insulin resistance. It is thought
More informationBackground EVM. FAO/WHO technical workshop on nutrient risk assessment, Geneva, May 2005, published 2006.
UK GOVERNMENT RESPONSE TO THE EUROPEAN COMMISSION S DISCUSSION PAPER ON THE SETTING OF MAXIMUM AND MINIMUM AMOUNTS FOR VITAMINS AND MINERALS IN FOODSTUFFS. Background The United Kingdom (UK) Government
More informationTitle: Elevated depressive symptoms in metabolic syndrome in a general population of Japanese men: a cross-sectional study
Author's response to reviews Title: Elevated depressive symptoms in metabolic syndrome in a general population of Japanese men: a cross-sectional study Authors: Atsuko Sekita (atsekita@med.kyushu-u.ac.jp)
More informationMorDHA. MorEPA. Omega-3 is an important building block for the development of the brain
MorDHA MorEPA MorDHA Omega-3 is an important building block for the development of the brain Our Western diet is rich in omega-6 fatty acids, but comprises insufficient omega-3 fatty acids. This causes
More informationPlease revise your paper to respond to all of the comments by the reviewers. Their reports are available at the end of this letter, below.
Dear editor and dear reviewers Thank you very much for the additional comments and suggestions. We have modified the manuscript according to the comments below. We have also updated the literature search
More informationT H E B E T T E R H E A L T H N E W S
W H O L E H E A L T H A M E R I C A. C O M Dr. Paul G. Varnas & WholeHealthAmerica.com present J U L Y, 2 0 1 3 V O L U M E 1 0, I S S U E 7 T H E B E T T E R H E A L T H N E W S P R O T E C T F R O M
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationTriglyceride-Lowering Therapies: Addressing Gaps in the Guidelines
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/triglyceride-lowering-therapies-addressing-gaps-inguidelines/8340/
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationWhere are we heading?
Unit 5: Where are we heading? Unit 5: Introduction Unit 1: What s in your food? Unit 2: How does your body use food? Unit 3: What is metabolic disease? Unit 4: How do I identify good and bad food? Unit
More informationTitle: Effects of short-term heart rate variability biofeedback on long-term abstinence in alcohol dependent patients - a one-year follow up
Author s response to reviews Title: Effects of short-term heart rate variability biofeedback on long-term abstinence in alcohol dependent patients - a one-year follow up Authors: Ana Isabel Penzlin (ana.penzlin@ppcr.org)
More informationFacts on Fats. Ronald P. Mensink
Facts on Fats Ronald P. Mensink Department of Human Biology NUTRIM, School for Nutrition, Toxicology and Metabolism Maastricht University Maastricht The Netherlands Outline of the Presentation Saturated
More informationTitle: Validation of the Comprehensive Feeding Practices Questionnaire with parents of 10-to-12-year-olds
Author's response to reviews Title: Validation of the Comprehensive Feeding Practices Questionnaire with parents of 10-to-12-year-olds Authors: Elisabeth L Melbye (elisabeth.l.melbye@uis.no) Torvald Øgaard
More informationThe cost-effectiveness of omega-3 supplements for prevention of secondary coronary events Schmier J K, Rachman N J, Halpern M T
The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events Schmier J K, Rachman N J, Halpern M T Record Status This is a critical abstract of an economic evaluation that
More informationHow a content-driven startup grew revenue 340% by avoiding social shortcuts. Chief Marketing Officer, TigerFitness.com
How a content-driven startup grew revenue 340% by avoiding social shortcuts Chief Marketing Officer, TigerFitness.com Chief Marketing Officer, TigerFitness.com To content and social media marketing
More informationAcasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C CaPre(R) Met All Primary and Key Secondary Endpoints Statistically
More informationThe use of omega-3 fatty acids in the management of cancer cachexia. Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust
The use of omega-3 fatty acids in the management of cancer cachexia Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust Overview Cancer cachexia Clinical features Pathogenesis
More informationn Promotes a healthy mood 1 n Supports attention and learning 2 n Supports normal memory as we age 3
n Promotes a healthy mood 1 n Supports attention and learning 2 n Supports normal memory as we age 3 n Protects nerve and brain cells from oxidative damage 4 Only with adequate intake of essential fatty
More informationFabio Akira Ito. Technical Services South America Pharma Ingredients & Services. Internal
Fabio Akira Ito Technical Services South America Pharma Ingredients & Services 1 Omega-3s and Health Benefits 2 Production of Omega-3 products 3 Argentinian Market 2 Definition of Major Omega-3 Polyunsaturated
More informationTitle:Impact of yoga on blood pressure and quality of life in patients with hypertension - a matched controlled trial in primary care
Author's response to reviews Title:Impact of yoga on blood pressure and quality of life in patients with hypertension - a matched controlled trial in primary care Authors: Moa Wolff (moa.wolff@med.lu.se)
More informationAuthor s response to reviews
Author s response to reviews Title: Treatment Completion for Latent Tuberculosis Infection: A Retrospective Cohort Study Comparing 9 months of Isoniazid, 4 months of Rifampin and 3 months of Isoniazid
More informationFREQUENTLY ASKED QUESTIONS
Myofusion Great Tasting Advanced Muscle Building Protein When it comes to the REAL nutritional needs of bodybuilders and athletes alike, there is little doubt what "legitimate" science has to say about
More informationMushrooms, Vitamin D and Cognition Human Studies
Mushrooms, Vitamin D and Cognition Human Studies Dr Louise Bennett CSIRO Food and Nutrition Project Number: MU12003 Co-authors: Ian Zajac, Paul Cavuoto, Mary Barnes, Vanessa Danthiir, Debra Krause, Peter
More informationJOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX COMMITTEE ON CONTAMINANTS IN FOODS 12 th Session Utrecht, The Netherlands, March 2018 PROPOSED
E Agenda Item 9 JOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX COMMITTEE ON CONTAMINANTS IN FOODS 12 th Session Utrecht, The Netherlands, 12-16 March 2018 CX/CF 18/12/9-Add.1 PROPOSED DRAFT CODE OF PRACTICE
More informationTitle:Dark chocolate and reduced snack consumption in mildly hypertensive adults: an intervention study
Reviewer's report Title:Dark chocolate and reduced snack consumption in mildly hypertensive adults: an intervention study Version:1Date:8 June 2015 Reviewer:Katherine Keene Reviewer's report: Minor Issues
More informationImpact of trans fats on health EFSA s work related to trans Fatty acids
Setting the scene Impact of trans fats on health EFSA s work related to trans Fatty acids Prof. Ambroise Martin Member of the EFSA WG on DRVs (former chair 2006-2015) and NDA Panel 2006-2015 (former chair
More informationFeatured Topic: Omega 7 and Omega 3 Fatty Acids (6 slides)
Featured Topic: Omega 7 and Omega 3 Fatty Acids (6 slides) Are you still afraid of fats? Do you buy skim milk and margarine? Do you snack on fat free crackers instead of nuts because nuts have too many
More informationDownloaded from:
Sydenham, E; Dangour, AD; Lim, WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev, 6 (6). CD005379. ISSN 1469-493X DOI: 10.1002/14651858.CD005379.pub3
More informationCan you reduce dementia risk through diet?
Can you reduce dementia risk through diet? Margaret P Rayman Professor of Nutritional Medicine University of Surrey Dietary Factors That May Protect Against Cognitive Decline and Alzheimer s Disease Antioxidants
More informationTitle: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives
Author s response to reviews Title: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives Authors: Robert Beckett (rdbeckett@manchester.edu) Kathryn
More information